Kiromic Biopharma, Inc.
KRBP evidence brief
What we can confirm
- BioSniper Score:
- 4.3 / 10
- Lead Asset:
- deltacel (Phase 1)
What it means
What to watch
Prepared research question
What matters most for KRBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
deltacel (Phase 1)
Next Catalyst
—
Tracking 2 pipeline candidates for Kiromic Biopharma, Inc..
Run Kiromic Biopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kiromic Biopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Kiromic Biopharma, Inc.'s lead drug candidate?
Kiromic Biopharma, Inc.'s most advanced tracked candidate is deltacel (Phase 1) for Non-small cell lung cancer (NSCLC).
Who is the CEO of Kiromic Biopharma, Inc.?
Brian Hungerford is the chief executive officer of Kiromic Biopharma, Inc. (KRBP).
What therapeutic areas does Kiromic Biopharma, Inc. focus on?
Kiromic Biopharma, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.